Title:
NANOVESICLES DERIVED FROM ENHYDROBACTER BACTERIA, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/172600
Kind Code:
A1
Abstract:
The present invention relates to vesicles derived from Enhydrobacter bacteria, and a use thereof. The present inventors experimentally confirmed that: compared to those of a normal person, the vesicles are significantly reduced in clinical samples from patients with pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, lymphoma, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, cirrhosis and diabetes; and when the vesicles isolated from a strain are administered, the secretion of inflammatory mediators by pathogenic vesicles, such as vesicles derived from Escherichia coli, is notably inhibited. Thus, the vesicles derived from Enhydrobacter bacteria, according to the present invention, may be usefully employed for the purpose of developing: a method for diagnosing pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, lymphoma, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, cirrhosis or diabetes; and a composition for preventing, improving or treating said diseases.
More Like This:
Inventors:
KIM YOON-KEUN (KR)
Application Number:
PCT/KR2019/002503
Publication Date:
September 12, 2019
Filing Date:
March 05, 2019
Export Citation:
Assignee:
MD HEALTHCARE INC (KR)
International Classes:
C12Q1/689; A23L33/135; A61K35/74; A61P35/00; A61P37/00; C12Q1/6851
Foreign References:
| KR101833348B1 | 2018-03-02 | |||
| KR20110025068A | 2011-03-09 | |||
| KR20160073157A | 2016-06-24 | |||
| KR20180006303A | 2018-01-17 | |||
| KR20180018354A | 2018-02-21 |
Other References:
See also references of EP 3763829A4
Attorney, Agent or Firm:
LEE, Myoung-Jin (KR)
Download PDF: